Comparison of 1- day and 2-days prophylactic antimicrobial administration for inhibiting surgical site infection (SSI) in Holmium Laser Enucleation of the prostate (HoLEP).
Not Applicable
Completed
- Conditions
- Benign prostate hyperplasia
- Registration Number
- JPRN-UMIN000027955
- Lead Sponsor
- Kobe Univerity
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
Those patients who do not agree with this study as a participant.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of SSI occurence
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain the efficacy of 1-day vs. 2-day antimicrobial prophylaxis in HoLEP for BPH?
How does 1-day antimicrobial prophylaxis in HoLEP compare to 2-day regimens in preventing SSI in BPH patients?
Which biomarkers predict SSI risk in patients undergoing HoLEP with varying antimicrobial durations?
What adverse event profiles are associated with 1-day versus 2-day antimicrobial regimens in HoLEP procedures?
What alternative antimicrobial agents or combination therapies are being explored for SSI prevention in HoLEP compared to JPRN-UMIN000027955?